Free Access
Issue
Med Sci (Paris)
Volume 32, Number 1, Janvier 2016
Origine développementale de la santé et des maladies (DOHaD), environnement et épigénétique
Page(s) 121 - 122
Section Prix Lasker 2015
DOI https://doi.org/10.1051/medsci/20163201020
Published online 05 February 2016
  1. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996 ; 271 : 1734–1736. [CrossRef] [PubMed] [Google Scholar]
  2. Brunet JF, Denizot F, Luciani MF, et al. A new member of the immunoglobulin superfamily, CTLA-4. Nature 1987 ; 328 : 267–270. [CrossRef] [PubMed] [Google Scholar]
  3. Walunas TL, Lenschow DJ, Bakker CY, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994 ; 1 : 405–413. [CrossRef] [PubMed] [Google Scholar]
  4. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995 ; 182 : 459–465. [Google Scholar]
  5. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010 ; 363 : 711–723. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.